Mainz Biomed (NASDAQ:MYNZ) Lowered to Hold Rating by Maxim Group

Mainz Biomed (NASDAQ:MYNZ) was downgraded by analysts at Maxim Group from a “strong-buy” rating to a “hold” rating in a note issued to investors on Friday,Zacks.com reports.

Other equities research analysts have also recently issued reports about the stock. Wall Street Zen upgraded shares of Mainz Biomed to a “hold” rating in a research note on Saturday, December 27th. Weiss Ratings reissued a “sell (e)” rating on shares of Mainz Biomed in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Mainz Biomed currently has a consensus rating of “Reduce”.

Mainz Biomed Stock Performance

MYNZ stock opened at $0.83 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.43 and a current ratio of 0.52. Mainz Biomed has a 1 year low of $0.55 and a 1 year high of $5.62. The stock’s fifty day moving average is $1.00 and its two-hundred day moving average is $1.28. The stock has a market capitalization of $7.52 million, a price-to-earnings ratio of -0.01 and a beta of 0.31.

Institutional Investors Weigh In On Mainz Biomed

Institutional investors have recently added to or reduced their stakes in the stock. Steward Partners Investment Advisory LLC lifted its holdings in shares of Mainz Biomed by 200.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 30,000 shares of the company’s stock valued at $34,000 after acquiring an additional 20,000 shares during the period. Armistice Capital LLC lifted its holdings in Mainz Biomed by 45.0% in the second quarter. Armistice Capital LLC now owns 285,000 shares of the company’s stock valued at $402,000 after buying an additional 88,400 shares during the period. Finally, Cerity Partners LLC bought a new stake in shares of Mainz Biomed in the 4th quarter valued at about $183,000.

About Mainz Biomed

Mainz Biomed AG is a molecular diagnostics company headquartered in Mainz, Germany, specializing in epigenetics-based tests for the early detection of cancer. The company develops proprietary assays that analyze DNA methylation patterns and other epigenetic biomarkers to identify malignancies at a stage when treatment outcomes are most favorable. Mainz Biomed’s technology platform is designed to offer non-invasive, easy-to-use screening solutions that can be deployed both in laboratory settings and at point of care.

The company’s flagship product, ColoAlert®, is a stool-based colorectal cancer screening test that combines DNA methylation markers with bacterial gene targets to improve sensitivity and specificity for detecting advanced adenomas and early-stage colorectal cancer.